ES2150989T3 - Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos. - Google Patents

Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.

Info

Publication number
ES2150989T3
ES2150989T3 ES94914313T ES94914313T ES2150989T3 ES 2150989 T3 ES2150989 T3 ES 2150989T3 ES 94914313 T ES94914313 T ES 94914313T ES 94914313 T ES94914313 T ES 94914313T ES 2150989 T3 ES2150989 T3 ES 2150989T3
Authority
ES
Spain
Prior art keywords
substd
opt
halo
phenyl
poxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914313T
Other languages
English (en)
Inventor
Andreas Huth
Lechoslaw Turski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4314591A external-priority patent/DE4314591A1/de
Priority claimed from DE19934344486 external-priority patent/DE4344486A1/de
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2150989T3 publication Critical patent/ES2150989T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE LA FORMULA (I), DONDE R 1 , R{SUP,5}, R{SUP,6}, R{SUP,7} Y R{SUP,8} TIENEN LOS SIGNIFICADOS CONOCIDOS EN LA APLICACION, ASI COMO SU ELABORACION Y UTILIZACION EN MEDICAMENTOS.
ES94914313T 1993-04-28 1994-04-28 Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos. Expired - Lifetime ES2150989T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4314591A DE4314591A1 (de) 1993-04-28 1993-04-28 Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE19934344486 DE4344486A1 (de) 1993-12-21 1993-12-21 Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln

Publications (1)

Publication Number Publication Date
ES2150989T3 true ES2150989T3 (es) 2000-12-16

Family

ID=25925529

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914313T Expired - Lifetime ES2150989T3 (es) 1993-04-28 1994-04-28 Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.

Country Status (23)

Country Link
US (2) US5750525A (es)
EP (2) EP1002796A3 (es)
JP (1) JP3530190B2 (es)
KR (1) KR100293880B1 (es)
CN (1) CN1053190C (es)
AT (1) ATE196474T1 (es)
AU (1) AU690550B2 (es)
CA (1) CA2161425A1 (es)
CZ (1) CZ290295B6 (es)
DE (1) DE59409534D1 (es)
DK (1) DK0696288T3 (es)
ES (1) ES2150989T3 (es)
FI (1) FI955140A0 (es)
GR (1) GR3035053T3 (es)
HU (1) HUT73676A (es)
IL (1) IL109397A0 (es)
NO (2) NO308902B1 (es)
NZ (1) NZ265599A (es)
PL (1) PL180332B1 (es)
PT (1) PT696288E (es)
RU (1) RU2140420C1 (es)
SK (1) SK282851B6 (es)
WO (1) WO1994025469A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057304A (en) * 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf
HU217837B (hu) * 1994-05-18 2000-04-28 EGIS Gyógyszergyár Rt. Savamidok, ezeket tartalmazó gyógyászati készítmények és eljárás a hatóanyagok előállítására
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
DE69524246T2 (de) * 1994-09-27 2002-06-27 Yamanouchi Pharma Co Ltd 1,2,3,4-Tetrahydroquinoxalindion Derivate und ihre Verwendung als Glutamat Rezeptor Antagonisten
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE19519979A1 (de) * 1995-05-24 1996-11-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
HUP9901345A3 (en) * 1995-07-10 2000-01-28 Novartis Ag Novel quinoxaline- and quinoxalinylalkane-phosphonic acids
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
BR9712651A (pt) * 1996-10-23 1999-10-26 Warner Lambert Co ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
EP0934326B1 (de) * 1996-10-24 2006-05-03 Novartis AG Substituierte aminoalkanphosphonsäuren
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE19737446A1 (de) * 1997-08-22 1999-02-25 Schering Ag Verfahren zur Herstellung von Phosphonsäurederivaten
DE69824025T2 (de) * 1997-09-01 2005-06-16 Kyorin Pharmaceutical Co., Ltd. 6,7-asymmetrisch disubstituierte chinoxalincarbonsäurederivate, additionssalze davon und verfahren zur herstellung von beiden
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
JP2002519373A (ja) * 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
AU767849B2 (en) 1999-02-15 2003-11-27 Eisai R&D Management Co., Ltd. Heterodiazinone derivatives
FR2791982B1 (fr) * 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
DE60137426D1 (de) 2000-06-12 2009-03-05 Eisai R&D Man Co Ltd 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
CN100490835C (zh) * 2004-12-14 2009-05-27 朱木林 一种治疗骨折的药物
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
MA54460A (fr) 2018-12-14 2021-10-20 Eisai R&D Man Co Ltd Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine
CN112142797B (zh) * 2020-09-11 2023-07-14 江西师范大学 含磷的喹喔啉类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
IL90315A0 (en) * 1988-06-01 1989-12-15 Ferrosan As Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse
JP2550456B2 (ja) * 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf

Also Published As

Publication number Publication date
SK282851B6 (sk) 2002-12-03
GR3035053T3 (en) 2001-03-30
US5955461A (en) 1999-09-21
US5750525A (en) 1998-05-12
DK0696288T3 (da) 2000-11-13
SK131895A3 (en) 1996-07-03
RU2140420C1 (ru) 1999-10-27
HU9503078D0 (en) 1995-12-28
NZ265599A (en) 1997-10-24
KR100293880B1 (ko) 2001-09-17
CZ290295B6 (cs) 2002-07-17
PT696288E (pt) 2001-01-31
JP3530190B2 (ja) 2004-05-24
PL317075A1 (en) 1997-03-03
NO20001604D0 (no) 2000-03-28
CA2161425A1 (en) 1994-11-10
PL180332B1 (pl) 2001-01-31
EP1002796A3 (de) 2001-09-12
EP0696288A1 (de) 1996-02-14
FI955140A (fi) 1995-10-27
IL109397A0 (en) 1994-07-31
AU6675594A (en) 1994-11-21
HUT73676A (en) 1996-09-30
WO1994025469A1 (de) 1994-11-10
DE59409534D1 (de) 2000-10-26
NO954315D0 (no) 1995-10-27
EP0696288B1 (de) 2000-09-20
NO20001604L (no) 1995-12-28
FI955140A0 (fi) 1995-10-27
CZ282895A3 (en) 1996-02-14
CN1053190C (zh) 2000-06-07
CN1153517A (zh) 1997-07-02
NO954315L (no) 1995-12-28
ATE196474T1 (de) 2000-10-15
EP1002796A2 (de) 2000-05-24
JPH08508037A (ja) 1996-08-27
NO308902B1 (no) 2000-11-13
NO311428B1 (no) 2001-11-26
AU690550B2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
SE8200815L (sv) Kemisk forening till anvendning som mellanprodukt vid framstellning av vissa triazolforeningar
MX9203262A (es) Agentes quelantes del acido 1,4,7,10-tetraazaciclododecano.
IL88784A0 (en) Substituted 6-phenyldihydro-3(2h)-pyridazinones,a process for their preparation and pharmaceutical preparations containing these compounds
DK0477778T3 (da) Benzen-, pyridin- eller pyrimidinderivat
SE8303987L (sv) N-fenylpyrazolderivat anvendbara som herbicider
ES8301196A1 (es) Procedimiento de preparacion de un nuevo derivado de acido cinamoil-cinamico
IL119054A0 (en) Substituted 4H-pyrans their preparation and pharmaceutical compositions containing them
FI955670A (fi) 2-aminobentseenisulfonihappo- ja 2-aminobentseenisulfonyyli kloridijohdannaiset, niiden valmistus ja käyttö synteesin välituotteina
ES464729A1 (es) Un procedimiento para la preparacion de benzisotiazolonas amino-alquil sustituidas.
FR2625199B1 (fr) Derives oxyimino du thiazole, procede de preparation et utilisation en therapeutique
FR2371198A2 (fr) Nouveaux derives du dithiepinno (1,4)(2,3-c) pyrrole, leur preparation et les compositions qui les contiennent
ATE1585T1 (de) Clavulansaeurederivate, ihre herstellung und sie enthaltende pharmazeutische praeparate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 696288

Country of ref document: ES